(Z)-2-(1H-咪唑-1-基)-1-(2,3,4-三甲氧基)苯乙酮肟酯的设计与合成

三甲基苯乙酮肟;立体异构体;(Z)-2-(1H-咪唑-1-基)-1-(2;3;4-三甲氧基)苯乙酮肟酯的设计与合成     

Synthesis of Two Isomeric Tetrasaccharides 0-α-L-Fucopyranosyl-(1→3) and (1→4)-0-(2-Acetamido-2-Deoxy-β-D-Glucopyranosyl)-(1→3)-0-(β-D-Galactopyranosyl)-(1→4)-D-Glucopyranose and a Related Tetrasaccharide 0-α-L-Fucopyranosyl-(1→3)-0-(2-Acetamido-2-Deoxy-β-D-Glucopyranosyl-(1→6)-0-(β-D-Galactopyranosyl)-(1→4)-D-Glucopyranose

ABSTRACT

Synthesis of three tetrasaccharides, namely, 0-α-L-fucopyranosyl-(1→3)-0-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→3)-0-(β-D-galactopyranosyl)-(1→4)-β-D-glucopyranose (7), 0-α-L-fucopyranosyl-(1→4)-0-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→3)-0-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (9), and 0-α-L-fucopyransoyl-(1→3)-0-(2-acetamido-2-deoxy-β-D-glucopyransoyl)-(1→6)-0-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (15) has been described. Their structures have been established by ¹³C NMR spectroscopy.     

2-苯基-1-(4-(1-吡咯乙氧基)苯基)乙酮的合成

2-苯基-1-(4-(1-吡咯乙氧基)苯基)乙酮是合成抗骨质疏松药拉索昔芬重要的结构片段。以苯酚为原料经成醚,磺酰氯酯化得到磺酸酯,然后经亲核取代反应,傅-克酰基化反应高收率地合成了目标化合物,其结构通过NMR和HRMS进行了表征。     

Synthesis,Structure and Biological Activities of 2-(1H- 1,2,3-Benzotriazol-1-yl)-1-(4-methylphenyl)-2- (1H-1,2,4-triazol-1-yl)-1-ethanone

IntroductionTriazole derivatives have become the most rapidlyexpanding group of antifungal compounds with advanta-ges of lowtoxicity, high oral bioavailability and broad-spectrum antifungal activity, which can be used againstfungi including most yeasts an…     

2-(1H-咪唑-1基)-1-(2,3,4-三甲氧基苯)乙酮的和成

联苯三醚;制备;2-(1H-咪唑-1基)-1-(2;3;4-三甲氧基苯)乙酮的和成     

1-(2,4-二氯苯基)-1-氨基-4,4-二甲基-2-(1,2,4-三唑-1-基)-3-戊酮(醇)的合成及生物活性研究

通过不同的胺对烯唑醇前体1的1,4-亲核加成反应,合成了目标化合物2,并将其还原得到了其还原产物3.生物活性测试结果发现,化合物3表现出较好的杀菌活性及一定程度的植物生长调节活性.     

Das 1-(4-Hydroxyphenyl)-1-hydroxy-2-n-butylamino-?thansulfat (Vasculat)

Ohne Zusammenfassung     

1-(4-氨基苯基)-2-(1-哌啶基)-1-丙酮盐酸盐的合成及其光引发性能

1-(4-氨基苯基)-2-(1-哌啶基)-1-丙酮盐酸盐的合成及其光引发性能;氨基苯乙酮;水溶性;光引发剂     

Stereoselective Synthesis and Characterization of (Z)-(−)-4-(1′-Alkoxyl-1′-alkyloxycarbonyl-methylidene)-5(R)-[(1R)-menthyloxy]-γ-butyrolactones

Abstract

A series of enantiomerically pure (Z)-(?)-4-(1′-alkyloxy-1′-alkyloxycarbonyl-methylidene)-5(R)-[(1R)-menthyloxy]-γ-butyrolactones were synthesized and characterized in good to excellent yields via O-alkylation of (4R,5R)-(?)-4-ethoxyoxalyl-5-[(1R)-menthyloxy]-γ-butyrolactone with alkyl halides in the presence of K₂CO₃ in acetone at room temperature.     

氟伐他汀中间体3-(4-氟苯基)-1-(1-异丙基)-1H-吲哚的合成

以苯胺为原料,经异丙基化、与2-氯-1-(4-氟苯基)乙酮缩合、催化分子内环合制得合成氟伐他汀的关键中间体——3-(4-氟苯基)-1-(1-异丙基)-1H-吲哚,总收率高于90%,其结构经1HNMR确证。     

EFFICIENT RESOLUTION OF (±)-1-(9-ANTHRYL)ETHYLAMINE

ABSTRACT

Conditions for efficient resolution of (±)-1-(9-anthryl)ethylamine ((±)-1) by fractional crystallization of its salts with (S)-(+)-mandelic acid (2) are reported. When crystallization was performed by fast addition of chloroform solution of an equivalent of (±)-1 to the hot chloroform solution of (+)-2, crystals of mandelate of (+)-1-(9-anthryl)ethylamine ((R,S)-3) are collected in 56% yield. (R)-(+)-1 (98.6% e.e.) is isolated by extraction from bicarbonate solution of mandelate salt. Ulterior collection of four crops afforded (R,S)-3 with 71.5% cumulative yield and >98% e.e. of (+)-1 in a any single crop. With only 0.5 equivalents of (+)-2 crystallization afforded (R,S)-3 in 47.4% yield and (+)-1 with 98.1% e.e.     

3,4-二氢-1-(4-哌啶基)-2(1H)-喹啉酮的合成

以苄胺为原料,经6步反应得到新型抗高血压药OPC-21268的中间体3,4-二氢-1-(4-哌啶基)-2(1H)-喹啉酮,总收率13．9％．     

Structural and bonding investigation of an unbridged donor-acceptor complex 1-(2,2′-bipyrimidine)-1-(t-butyl)-2, 3-bis(trimethylsilyl) -2,3-dicarba-1-galla-closo-heptaborane(6)

The reaction between thecloso-gallacarborane, 1-(t-C₄H₉)-1-Ga-2,3-(SiMe₃)₂-2,3-C₂B₄H₄ (1), and 2,2-bipyrimidine in a molar ratio of 11 in dry benzene produced the unbridged donor-acceptor complex 1-(2,2-C₈H₆N₄)-1-(t-C₄H₉)-1-Ga-2,3-(SiMe₃)₂-2, 3-C₂B₄H₄ (2) as a pale-yellow crystalline solid in 81% yield. The spectroscopic data of2 are almost identical to those of the bridged species 1,1-(2,2-C₈ H₆N₄)-[1-(t-C₄H₉)-1-Ga-2,3-(SiMe₃)₂-2,3-C₂ B₄H₄]₂ (3). However, the single-crystal X-ray structure of2 reveals that the complex consists of only one distorted gallacarborane unit and a bipyrimidine molecule, that acts as a bidentate ligand. The apical gallium in2 is displaced further away from the centroidal position above the carborane than it is in 1. Despite the steric hindrance imposed by the bulky trimethylsilyl groups on the cage carbons, the Ga-C_(t-buty) bond is tilted toward the cage carbon atoms. Complex2 crystallizes in the monoclinic space groupP2₁ witha=11.279 (3),b=10.060 (3),c=11.911 (3) Å,=94.94 (2)°,V=1346.5 (6) ų,Z=2,D _x=1.24g cm^–3, (MoK) F(000)= 528, andT=220 K. Full-matrix least-squares refinement for2 converged at R=0.036 andRw= 0.045 for 3032 observed reflections. Molecular orbital calculations showed that antibonding interactions between the gallium and carborane cage carbons, induced by base complexation, are a contributing factor to the gallium's slip distortion that is found in2.     

(S)-2,2,2-三氟-1-(2-甲基-1H-1-吲哚基)乙胺的不对称合成

以2-甲基吲哚为原料,在碱性条件下与α-三氟甲基醛亚胺经加成反应合成了关键中间体——含三氟甲基的(S)-叔丁基亚磺酰胺(3),收率95%,d/r99/1;3脱除保护基得(S)-2,2,2-三氟-1-(2-甲基-1H-1-吲哚基)乙胺(4),收率97%,其结构经1H NMR,13C NMR,19F NMR,FT-IR,EI-MS和HR-EI-MS确证。     

2-(2,4-二氟苯基)-1-(4-烃基派嗪-1-基)-3-(1,2,4-三唑-1-基)-2-丙醇类化合物的合成及抗真菌活性

近20年来,真菌感染特别是深部真菌感染日益引起人们的广泛关注[1]。三唑类抗真菌药物对真菌的选择性较高,代谢稳定,体内动态、安全性都较好,已成为目前抗真菌药物研究开发的重点[2]。三唑类抗真菌药物是细胞色素P450 14α 去甲基酶的抑制剂,可影响该酶所催化的真菌麦角甾醇的生物合成,导致真菌细胞膜破损而死亡[3,4]。1998年,SynPhar实验室及Taiho制药公司[5]研制开发的化合物Syn 2869采用了取代哌嗪作为侧链。体外实验表明,该化合物抗菌谱广,对多种念珠菌、隐球菌及曲莓菌均有效,体内实验中,与目前临床上治疗真菌感染的主要用药伊曲…     

4-(4-Chlorophenyl)-3,7,7-trimethyl-1-[2-(4-nitrobenzoyl)ethyl]-4,7,8,9-tetrahydro-1H-pyrazolo[3,4-b]quinolin-5(6H)-one–ethanol (1/1)

Molecules of the title compound, C₂₈H₂₇ClN₄O₄·C₂H₆O, form a C(6) chain via an N—H⋯O hydrogen bond along the c axis by the operation of a c-glide plane, with N⋯O = 2.761 (3) Å and N—H⋯O = 165°. The mol­ecules are further linked by a weak C—H⋯O interaction, with C⋯O = 3.344 (4) Å and C—H⋯O = 150°. Pendant hydrogen-bonded ethanol solvent mol­ecules are attached to the chains by O—H⋯N hydrogen bonds, with O⋯N = 2.904 (3) Å and O—H⋯N = 175°.     

Investigation of supramolecular inclusion complexes with β-cyclodextrin of 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-hydroxypiperidine and 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-benzoyloxypiperidine oxalate by NMR spectroscopy

A comparative analysis of ¹H and ¹³C NMR spectra of 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-hydroxypiperidine, 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-benzoyloxypiperidine oxalate and their inclusion complexes with β-cyclodextrin was performed. The differences in values of chemical shifts of ¹H and ¹³C nuclei of the substrates and the receptor in the inclusion complexes were determined. It was found that the formation of complexes of 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-hydroxypiperidine and 1-(2-ethoxyethyl)-4-(pentyn-1-yl)-4-benzoyloxypiperidine oxalate with β-cyclodextrin was accompanied by insertion of one N-ethoxyethyl fragment of the substrate molecule into the inner sphere of one molecule of the receptor.     

含1,2-双(3,5-二氧哌嗪-1)乙烷和(±)-1,2-双(3,5-二氧哌嗪-1)丙烷低聚物的合成

<正> 将低分子药物或有药理活性的基团,通过高分子化,所得的高分子药物,具有较高的为细胞吞噬或胞饮等活性,并期望它们在体内崩解缓释,与相应的低分子药物相比,可以发挥长效、低毒的优点。 1,2双-(3,5-二氧哌嗪-1)乙烷和(±)1,2双(3,5-二氧哌嗪-1)丙烷,是临床使用     

Synthesis of propyl O-(α-L-rhamnopyranosyl)-(1→3)-[2,4-di-O-(2s-methylbutyryl)-α-L-rhamno-pyranosyl]-(1→2)-(3-O-acetyl-β-D-glucopyranosyl)-(1→2)-β-D-fucopyranoside,the tetrasaccharide moiety of Tricolorin A

Propyl O-(α-L-rhamncpyranosyl)-(1→3)-[2,4-di-O-(2s-methylbutyryl)-α-L-rham-nopyranosyl]-(1→2)-(3-O-acetyl-β-D-glucopyranosyl)-(1→2)-β-D-fucopyranoside (1), the tetrasac-charide moiety of Tricolorin A, was synthesized in total 23 steps with a longest linear sequence of 10 steps, and overall yield of 3.7% from D-Glucose. The isomerization of the dioxolane-type berzyli-dene in the presence of NIS/AgOTf was observed. Tetrasaccharide 1 exhibited no activity against the cultured P388 cell as Tricolorin A did.     

(S)-1-[2-(3-羟基金刚烷-1-氨基)乙酰基]吡咯烷-2-甲酰胺的合成

为了对维格列汀进行质量控制,合成了其相关物质:(S)-1-[2-(3-羟基金刚烷-1-氨基)乙酰基]吡咯烷-2-甲酰胺(1)。本文以L-脯氨酸和盐酸金刚烷胺为原料,经仲N-氯乙酰化,酰胺化,氨基取代3步反应合成,合成的物质其结构经MS、1H-NMR和13C-NMR确证,纯度经HPLC检测亦符合国家药品生物制品检定所的规定。应用星点设计-效应面法优化工艺后,提高了其收率和纯度,具有重要的应用价值。